• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Cyr61/CCN1 与纤连蛋白的 somatomedin B(1-44)结构域具有高亲和力结合。

Cyr61/CCN1 displays high-affinity binding to the somatomedin B(1-44) domain of vitronectin.

机构信息

Section of Vector Biology, Laboratory of Malaria and Vector Research, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

出版信息

PLoS One. 2010 Feb 26;5(2):e9356. doi: 10.1371/journal.pone.0009356.

DOI:10.1371/journal.pone.0009356
PMID:20195466
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2829074/
Abstract

BACKGROUND

Cyr61 is a member of the CCN (Cyr61, connective tissue growth, NOV) family of extracellular-associated (matricellular) proteins that present four distinct functional modules, namely insulin-like growth factor binding protein (IGFBP), von Willebrand factor type C (vWF), thrombospondin type 1 (TSP), and C-terminal growth factor cysteine knot (CT) domain. While heparin sulphate proteoglycans reportedly mediate the interaction of Cyr61 with the matrix and cell surface, the role of other extracellular associated proteins has not been revealed.

METHODS AND FINDINGS

In this report, surface plasmon resonance (SPR) experiments and solid-phase binding assays demonstrate that recombinant Cyr61 interacts with immobilized monomeric or multimeric vitronectin (VTNC) with K(D) in the nanomolar range. Notably, the binding site for Cyr61 was identified as the somatomedin B domain (SMTB(1-44)) of VTNC, which mediates its interaction with PAI-1, uPAR, and integrin alphav beta3. Accordingly, PAI-1 outcompetes Cyr61 for binding to immobilized SMTB(1-44), and Cyr61 attenuates uPAR-mediated U937 adhesion to VTNC. In contrast, isothermal titration calorimetry shows that Cyr61 does not display high-affinity binding for SMTB(1-44) in solution. Nevertheless, competitive ELISA revealed that multimeric VTNC, heat-modified monomeric VTNC, or SMTB(1-44) at high concentrations attenuate Cyr61 binding to immobilized VTNC, while monomeric VTNC was ineffective. Therefore, immobilization of VTNC exposes cryptic epitopes that recognize Cyr61 with high affinity, as reported for a number of antibodies, beta-endorphin, and other molecules.

CONCLUSIONS

The finding that Cyr61 interacts with the SMTB(1-44) domain suggests that VTNC represent a point of anchorage for CCN family members to the matrix. Results are discussed in the context of the role of CCN and VTNC in matrix biology and angiogenesis.

摘要

背景

Cyr61 是细胞外基质相关(基质细胞)蛋白的 CCN(Cyr61、结缔组织生长因子、NOV)家族的成员,具有四个不同的功能模块,即胰岛素样生长因子结合蛋白(IGFBP)、血管性血友病因子 C 型(vWF)、血小板反应蛋白 1 型(TSP)和 C 端生长因子半胱氨酸结(CT)域。肝素硫酸蛋白聚糖据称介导 Cyr61 与基质和细胞表面的相互作用,但其他细胞外相关蛋白的作用尚未揭示。

方法和发现

在本报告中,表面等离子体共振(SPR)实验和固相结合实验表明,重组 Cyr61 与固定化单体或多聚体 vitronectin(VTNC)相互作用,K(D) 值在纳摩尔范围内。值得注意的是,Cyr61 的结合位点被确定为 VTNC 的 somatomedin B 结构域(SMTB(1-44)),该结构域介导其与 PAI-1、uPAR 和整合素 alphav beta3 的相互作用。因此,PAI-1 竞争 Cyr61 与固定化 SMTB(1-44)的结合,Cyr61 减弱 uPAR 介导的 U937 对 VTNC 的黏附。相反,等温滴定量热法显示 Cyr61 在溶液中对 SMTB(1-44)没有显示出高亲和力结合。然而,竞争性 ELISA 显示,多聚体 VTNC、热改性单体 VTNC 或高浓度的 SMTB(1-44) 减弱 Cyr61 与固定化 VTNC 的结合,而单体 VTNC 则无效。因此,VTNC 的固定化暴露了识别 Cyr61 的高亲和力隐匿表位,正如许多抗体、β-内啡肽和其他分子的报道。

结论

Cyr61 与 SMTB(1-44)结构域相互作用的发现表明,VTNC 代表 CCN 家族成员与基质的锚定点。结果在 CCN 和 VTNC 在基质生物学和血管生成中的作用的背景下进行了讨论。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e7/2829074/f33e8e2abe93/pone.0009356.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e7/2829074/831e203d90e2/pone.0009356.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e7/2829074/4ce23d5d6e85/pone.0009356.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e7/2829074/d7fa727d737d/pone.0009356.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e7/2829074/2c00ff309e6a/pone.0009356.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e7/2829074/d26e767ff2f5/pone.0009356.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e7/2829074/f33e8e2abe93/pone.0009356.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e7/2829074/831e203d90e2/pone.0009356.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e7/2829074/4ce23d5d6e85/pone.0009356.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e7/2829074/d7fa727d737d/pone.0009356.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e7/2829074/2c00ff309e6a/pone.0009356.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e7/2829074/d26e767ff2f5/pone.0009356.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e7/2829074/f33e8e2abe93/pone.0009356.g006.jpg

相似文献

1
Cyr61/CCN1 displays high-affinity binding to the somatomedin B(1-44) domain of vitronectin.Cyr61/CCN1 与纤连蛋白的 somatomedin B(1-44)结构域具有高亲和力结合。
PLoS One. 2010 Feb 26;5(2):e9356. doi: 10.1371/journal.pone.0009356.
2
Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin.纤溶酶原激活物抑制剂-1通过与玻连蛋白的生长调节素B结构域结合来调节细胞黏附。
J Cell Physiol. 2001 Oct;189(1):23-33. doi: 10.1002/jcp.1133.
3
The reduced, denatured somatomedin B domain of vitronectin refolds into a stable, biologically active molecule.纤连蛋白减少、变性的生长调节素B结构域可重新折叠成稳定的生物活性分子。
Biochemistry. 2006 Mar 14;45(10):3297-306. doi: 10.1021/bi052278f.
4
Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin.玻连蛋白生长调节素B结构域中纤溶酶原激活物抑制剂-1结合基序的结构与功能分析
J Biol Chem. 1996 May 31;271(22):12716-23. doi: 10.1074/jbc.271.22.12716.
5
Functional structure of the somatomedin B domain of vitronectin.玻连蛋白生长调节素B结构域的功能结构
Protein Sci. 2007 Jul;16(7):1502-8. doi: 10.1110/ps.072819107. Epub 2007 Jun 13.
6
A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity.缺乏生长调节素B结构域的玻连蛋白缺失突变体表现出纤溶酶原激活物抑制剂-1结合活性。
J Biol Chem. 2008 Apr 18;283(16):10297-309. doi: 10.1074/jbc.M708017200. Epub 2008 Jan 3.
7
A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin.一种确定蛋白质-蛋白质相互作用中涉及的结合位点的方法:纤溶酶原激活物抑制剂1与玻连蛋白生长调节素结构域结合的分析
Anal Biochem. 2001 Sep 15;296(2):245-53. doi: 10.1006/abio.2001.5316.
8
Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin.人玻连蛋白生长调节素B结构域活性形式中的二硫键连接方式。
Biochemistry. 2004 Jun 1;43(21):6519-34. doi: 10.1021/bi049647c.
9
Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.尿激酶受体上玻连蛋白结合位点的定位:由结构域I和侧翼结构域间连接区的残基组成的连贯受体界面的参与。
J Biol Chem. 2007 May 4;282(18):13561-72. doi: 10.1074/jbc.M610184200. Epub 2007 Mar 13.
10
The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.尿激酶型纤溶酶原激活物(uPA)受体和玻连蛋白的生长调节素B区域将uPA定位于微血管内皮细胞的粘着斑。
Matrix Biol. 2007 Jun;26(5):359-70. doi: 10.1016/j.matbio.2007.01.009. Epub 2007 Feb 6.

引用本文的文献

1
An overview of CCN4 (WISP1) role in human diseases.CCN4(WISP1)在人类疾病中的作用概述。
J Transl Med. 2024 Jun 27;22(1):601. doi: 10.1186/s12967-024-05364-8.
2
Thrombin alters the synthesis and processing of CYR61/CCN1 in human corneal stromal fibroblasts and myofibroblasts through multiple distinct mechanisms.凝血酶通过多种不同机制改变人角膜基质成纤维细胞和肌成纤维细胞中CYR61/CCN1的合成与加工。
Mol Vis. 2020 Jul 29;26:540-562. eCollection 2020.
3
Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.

本文引用的文献

1
The CCN family of proteins: structure-function relationships.CCN蛋白家族:结构与功能的关系
Trends Biochem Sci. 2008 Oct;33(10):461-73. doi: 10.1016/j.tibs.2008.07.006. Epub 2008 Sep 11.
2
Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain.纤溶酶原激活物抑制剂-1上与生长调节素B结构域之外的玻连蛋白结合位点的特征分析
J Biol Chem. 2008 Oct 17;283(42):28487-96. doi: 10.1074/jbc.M804257200. Epub 2008 Jul 24.
3
Functional domains of CCN1 (Cyr61) regulate breast cancer progression.CCN1(Cyr61)的功能结构域调节乳腺癌进展。
Cyr61和YB-1是uPAR新的相互作用伙伴,并提高三阴性乳腺癌的恶性程度。
Oncotarget. 2016 Jul 12;7(28):44062-44075. doi: 10.18632/oncotarget.9853.
4
Molecular control of vascular development by the matricellular proteins () and ().基质细胞蛋白()和()对血管发育的分子调控
Trends Dev Biol. 2013;7:59-72.
5
Cysteine-rich protein 61 (CCN1) and connective tissue growth factor (CCN2) at the crosshairs of ocular neovascular and fibrovascular disease therapy.富含半胱氨酸的蛋白 61(CCN1)和结缔组织生长因子(CCN2)在眼部新生血管和纤维血管疾病治疗的交汇点。
J Cell Commun Signal. 2013 Dec;7(4):253-63. doi: 10.1007/s12079-013-0206-6. Epub 2013 Jun 7.
6
Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets.靶向细胞外基质:CCN 蛋白作为新兴的治疗靶点。
Nat Rev Drug Discov. 2011 Dec 1;10(12):945-63. doi: 10.1038/nrd3599.
7
Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors.激肽释放酶相关肽酶 12 水解细胞基质细胞外基质蛋白 CCN 家族,并改变 CCN1 和 CCN5 与生长因子的相互作用。
J Biol Chem. 2011 Jul 22;286(29):25505-18. doi: 10.1074/jbc.M110.213231. Epub 2011 May 31.
8
Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.纤连蛋白在间质中积累,但对实验性慢性肾脏病的纤维化影响极小。
Am J Physiol Renal Physiol. 2011 May;300(5):F1244-54. doi: 10.1152/ajprenal.00701.2010. Epub 2011 Jan 26.
9
The matricellular protein cysteine-rich protein 61 (CCN1/Cyr61) enhances physiological adaptation of retinal vessels and reduces pathological neovascularization associated with ischemic retinopathy.基质细胞衍生蛋白胱氨酸丰富蛋白 61(CCN1/Cyr61)增强视网膜血管的生理适应能力,并减少与缺血性视网膜病变相关的病理性新生血管形成。
J Biol Chem. 2011 Mar 18;286(11):9542-54. doi: 10.1074/jbc.M110.198689. Epub 2011 Jan 6.
Int J Oncol. 2008 Jul;33(1):59-67.
4
Structure and ligand interactions of the urokinase receptor (uPAR).尿激酶受体(uPAR)的结构与配体相互作用
Front Biosci. 2008 May 1;13:5441-61. doi: 10.2741/3092.
5
Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes.两种人玻连蛋白、尿激酶及尿激酶受体复合物的晶体结构。
Nat Struct Mol Biol. 2008 Apr;15(4):422-3. doi: 10.1038/nsmb.1404. Epub 2008 Mar 23.
6
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.卵巢癌细胞转移的初始步骤由玻连蛋白和纤连蛋白的基质金属蛋白酶-2切割介导。
J Clin Invest. 2008 Apr;118(4):1367-79. doi: 10.1172/JCI33775.
7
Blood coagulation, inflammation, and malaria.血液凝固、炎症与疟疾。
Microcirculation. 2008 Feb;15(2):81-107. doi: 10.1080/10739680701451516.
8
A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity.缺乏生长调节素B结构域的玻连蛋白缺失突变体表现出纤溶酶原激活物抑制剂-1结合活性。
J Biol Chem. 2008 Apr 18;283(16):10297-309. doi: 10.1074/jbc.M708017200. Epub 2008 Jan 3.
9
Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent.纤溶酶原激活物抑制剂-1的结构-功能关系及其作为治疗剂的潜力。
Curr Drug Targets. 2007 Sep;8(9):971-81. doi: 10.2174/138945007781662337.
10
Solution structure of recombinant somatomedin B domain from vitronectin produced in Pichia pastoris.在毕赤酵母中产生的玻连蛋白重组生长调节素B结构域的溶液结构
Protein Sci. 2007 Sep;16(9):1934-45. doi: 10.1110/ps.072949607.